Emerging roles of microRNAs as diagnostics and potential therapeutic interest in type 2 diabetes mellitus

Table 3 miRNAs expression in metabolic disease and reported therapeutic approaches

No.	miRNA	Model	Method	Disease	Target	Ref.
1	miR-210	H9c2 cells (rat embryonic cardiac myoblast; ATCC)	miR-210 mimic and inhibitor	Diabetic cardiomyopathy	c-Jun N-terminal kinase (JNK)	[54]
2	miR-29b	db/db mice	Ultrasound-microbubble–mediated gene transfer technique was used to deliver doxycline (Dox)-inducible pre-miR-29b	Diabetic nephropathy	TGF-β/Smad3	[71]
3	miR-146a	HaCaT cells	Mimic and inhibitor miR-146a deliver via lipofecter liposomal transfection	Diabetic foot ulcer	AKAP12, Wnt3a and β-catenin	[72]
4	miRNA-339	Endothelial progenitor cell of humans	Transfection with miRNA-339-5p mimic or miRNA-339-5p inhibitor	Polycystic ovary syndrome	PI3K, AKT and SIRT1 PGC-1α	[73]
5	miR-21	C6 glioblastoma cells	Antagomir-21/RAP nanoparticles	Intracranial glioblastoma	PTEN and PDCD4	[74]
6	miR-107 and miR-103	C57BL/6J	Antagomir of miR-103 and miR-107 delivered by liver-targeting lipid nanoparticle	Diabetes	Caveolin-1	[75]
7	miR-181a	Mouse neuroblastoma cells (Neuro2A) and HEK293T cells and male sprague dawley rats	AMO181a-chol loaded exosomes	Cerebral ischemia	Hypoxia-induced RAGE and Bcl2	[76]

RAGE: Receptor of advanced glycation end products; TGF: Tumor growth factor.